Renal cell carcinoma (RCC) is the most common tumor of the adult kidney, accounting for -85% of renal neoplasms: RCC is heterogeneous in appearance, displaying diverse histologic and cytologic characteristics, with the clear cell variant being the most common. Individuals at high risk for this disease include persons with end-stage renal disease, those with hereditary predispositions such as von Hippel-Lindau syndrome (VHL) or tuberous sclerosis (TSC), and individuals with significant environment exposures such as smoking or analgesic abuse. Recently, several of the genetic targets for alterations involved in the development of human RCC have been identified. Solid RCC of the clear cell type is associated with alterations in the VHL tumor suppressor gene and hereditary papillary RCC is associated with alterations of the c-met protooncogene. In the rat, the most commonly seen tumors are of the non-clear cell type and it is the Tsc-2 tumor suppressor gene, rather than the VHL tumor suppressor gene, that appears to be the primary target for both spontaneous and carcinogen-induced mutations in these animals. These data suggest that different variants of RCC have distinct molecular etiologies and that there are species-specific determinants that modulate the involvement of specific tumor suppressor genes in RCC. Interestingly, many of the genes involved in RCC also play significant roles in kidney development. The Wilm's tumor suppressor gene, WT-1, and Pax-2 regulate the mesenchymal epithelial transition that occurs during nephrogenesis and both these genes exhibit altered expression patterns andor are mutated in renal tumors. Other genes such as c-met and its ligand hepatocyte growth factor are also involved in normal development and tumorigenesis, suggesting that tumors arise as a result of altered functions that are reflective of events that occur during nephrogenesis.
disease causation is an open question. In some cases, distinct chromosome alterations have been observed for specific RCC variants. In fact, it has been suggested by Kovacs and others that a genetic approach to tumor diagnosis based on the pattern of chromosome alterations observed in particular tumors would be a more appropriate and clinically relevant strategy than the currently used histological and cytological criteria (40, 77) . For example, papillary tumors exhibit trisomies of chromosomes 7, 16 , and 17 and loss of the Y chromosome, whereas clear cell tumors are characterized by chromosome 3p deletions and trisomy of 5q (41), suggesting that distinct molecular alterations are involved in the development of these two RCC variants. The kidneys of patients with papillary RCC also often contain many focal areas of undifferentiated blastemal cells, so-called "metanephric rests," a finding specific to papillary RCC and which has been suggested to be evidence that papillary RCC may arise as a consequence of abortive nephrogenesis (40) . In contrast to as recently as 5 yr ago, when specific genes WALKER TOXICOLOGIC PATHOLOGY (47) . its involvement in tumorigenesis appears to be restricted to RCC and some of the otherwise rare malignancies that occur with a high frequency in this syndrome, such as hemangioblastoma (34, 53) , suggesting a tissue-specific function of its tumor suppressor activity. The protein product of. the VHL gene can interact with several molecules involved in transcription elongation (8), although the lack of evidence that VHL regulates this process and the fact that mutations in VHL do not appear to abrogate its elongin association suggest that altered transcription elongation may not be the major pathway by which this gene functions in tumorigenesis.
Recent data suggest that VHL may be acting predominantly to regulate cell cycle arrest and the transition to quiescence under conditions in which cells transit to Go such as serum starvation (55). Under these conditions, VHL appears to transduce the signal to growth arrest in response to growth factor depletion via changes in the stability of p27 (55). Interestingly, loss of VHL function correlates with increased expression of the angiogenesis factor vascular endothelial growth factor (VEGF), which is overexpressed in well-vascularized tumors such as RCC (68, 87) . Reintroduction of wild-type VHL suppresses VEGF expression and tumor cell growth iii vivo. consistent with modulation of angiogenesis by VHL playing a key role in tumorigenesis (4, 29) . VHL is also a useful illustration that specific molecular alterations can be diagnostic for specific types of RCC, as this gene is involved exclusively in the clear cell but not other variants of this disease (17), consistent with the hypothesis that distinct molecular etiologies may exist for different RCC variants.
The TSC-2 Timor Suppressor Geite
The human TSC-2 tumor suppressor gene located on chromosome 16 was cloned by the European Tuberous Sclerosis Consortium (1 1) and its tumor suppressor function was first demonstrated for RCC in the Eker rat model (see below). Loss of heterozygosity of TSC-2 has also been shown to occur in renal hamartomas (3, 20, 24, 65) and other tumors that frequently occur in tuberous sclerosis patients (20). The TSC-2 gene product, tuberin, is widely expressed in most adult tissues including the kidney (85) and it has been shown to regulate GTPase activity for at least 2 proteins involved in ras signal transduction, Rap-la and rab5 (84. 89) . However, the function of this gene in the development of benign (hamartomas) or malignant (RCC) renal tumors has not been established.
Tke c-met Protooncogene
Hereditary RCC of the papillary variety has recently been shown to occur as a result of a germline mutation in the c-met protooncogene (64). In epithelial cells, c-met functions as a receptor tyrosine kinase for hepatocyte growth factor (HGF) and germline mutations in this gene constitutively adtivate its kinase function.. Few data are available on the involvement of this gene in other RCC variants or the frequency with which c-met is mutated in spontaneous papillary renal tumors as only 1/60 sporadic tumors examined contained a c-met mutation resulting in an amino acid substitution (64). Alterations in c-met observed in hereditary papillary RCC may be reflective of the critical role of c-met observed in the mesenchymalepithelial transition that takes place prior to tubulogenesis . and is a requisite part of normal kidney development (see below).
NEPHROGENESIS AS A FRAhlEWORK FOR UNDERSTANDING
THE MOLECULAR ETIOLOGY OF RCC The genes that direct many of the processes involved in nephrogenesis have been identified (Fig. I) , and as cancer is often viewed as an aberration of normal developmental processes, it not surprising that genes involved in nephrogenesis also participate in renal tumorigenesis. During kidney development, nephrogenesis is initiated by the ureteric bud as it contacts metanephric mesenchyme to induce these cells to undergo a mesenchymal-epithelial transition and to participate in the process of tubulogenesis. As shown in Fig. 1 , the diffuse metanephric mesenchyme condenses in response to inductive signals from the ureteric bud and acquires epithelial characteristics. This newly formed epithelium begins to assume the characteristic morphologic appearance of comma-and S-shaped bodies as the nascent tubular structures form. These epithelial cells then fuse with the ureteric bud to form the tubular portions of the mature nephron and the epithelial cells (podocytes) of the glomerulus. During this process, endothelial cells are recruited into the terminal end of the developing tubule to form the capillary tufts of the glomerulus, and it is within this glomerulus that the mesangial cells also develop (9, 54, 86) . For several genes whose roles in nephrogenesis are well established, there is equally compelling evidence that they play important roles in tumorigenesis.
The Wilnts Tunior Suppressor Gene
The Wilms tumor suppressor gene WT-1 is involved in the mesenchymal-epithelial transition of the metanephric blastema (58). Consistent with its function as a growth suppressor, WT-1 is not expressed by undifferentiated proliferating mesenchyme, but in response to increased expression of the transcription factor Pax-2 following condensation of the renal vesicle, WT-1 is turned on and is required for the differentiation of these mesenchymal cells (7). WT-1 in turn downregulates Pax-2 expression as the process of tubulogenesis is completed (62), with low levels of WT-1 persisting only in the podocyte layer of the glomerulus in the adult kidney. Loss of function and/or mutation of the WT-1 tumor suppressor gene is involved in the development of nephroblas- toma (a pediatric kidney tumor) but not RCC (21), consistent with its expression within metanephric blastema and the lack of expression of this gene by mature tubular epithelial cells of the renal nephron that are the progenitors of RCC.
HGF mid Its Cognate Receptor c-met
Another signaling pathway involved in the mesenchy-ma1 epithelial transition of nephrogenesis with links to tumorigenesis is met/HGF (61, 63, 73, 88) . HGF is expressed by the metanephric mesenchyme and its receptor, c-met, is expressed by both the ureteric bud and metanephric mesenchyme itself (70) . This signaling cascade may be involved in the branching morphogenesis of the ureteric bud induced by HGF-secreting mesenchymal cells and the coexpression of c-met and HGF by these mesenchymal cells may also play a key role in their proliferation prior to epithelialization. In support of this hypothesis, it has been shown that neutralizing antibodies to HGF that block this signaling pathway induce apoptosis in the renal mesenchyme in organ culture and inhibit branching morphogenesis and epithelialization (63, 88) . In vivo, upon epithelialization of mesenchymal blastema, HGF expression is downregulated while c-met continues to be expressed by the newly epithelialized cells (70) . As mentioned above, it has recently been shown that hereditary papillary RCC results from a germline mutation of c-met, suggesting that in tumors, this mutation results in constitutive activation and continued signaling of this receptor' after HGF production would normally have been downregulated following the epithelialization of the mesenchymal cells.
The Hoiiieobox Geiie Pax-2
The Pax gene family encodes proteins with a characteristic DNA binding motif (the "paired domain") that function as transcription factors. The data for the involvement of Pax-2 in early nephrogenesis is quite clear and its involvement in RCC has also been well documented (16). Similar to human RCC, Pax-2 is reexpressed in rat RCC (unpublished data), suggesting a common mechanism of deregulated expression in tumors from different species (rat and human) and different phenotypes (clear cell vs chromophilic). Although regulation of Pax-:! by WT-1 has been shown (62), the lack of WT-1 expression in both adult kidney epithelial cells that do not express Pax-2 and RCC that reexpress this gene suggests that transcription factors other than WT-1 participate in Pax-2 regulation in RCC.
COMPARATIVE GENETICS OF RENAL CARCINOGENESIS IN RATS AND HUMANS The Eker Rat In Vivolln Vitro Model for RCC
An animal model for RCC has been identified that has been developed into an in vivolin vitro model system for studying mechanisms of renal carcinogenesis. As shown in Fig. 2 , in the Eker rat model, animals heterozygous for a germline alteration in the Tsc-2 tumor suppressor gene are predisposed to develop spontaneous tumors of the kidney, uterus and spleen. RCC develops in 100% of gene carriers by 12 mo of age and uterine leiomyomas are present in >60% of carrier females by 16 mo of age (12). Hemangiosarcoma incidence has not been quantitated precisely, but it approaches 50% in carrier males (unpublished data). Homozygous wild-type animals are normal with a low frequency of spontaneous RCC equivalent to the background incidence of these tumors of <0.5% in the Long-Evans strain of rat on which the Eker mutation is carried (69) . Interestingly, homozygosity of the mutant Tsc-2 allele is embryolethal.
The hereditary predisposition to RCC in these rats was first recognized by Eker in the early 1960s and characterized as a single trait with a classic autosomal dominant pattern of inheritance (10). Studies by our laboratory and others demonstrated that the Eker mutation predisposed to both spontaneous and carcinogen-induced RCC (26, 81, go), and in 1994 it was determined that this mutation resided in the Tsc-2 gene (37, 92) . Tuberous sclerosis has an autosomal dominant pattern of inheritance characterized by benign lesions of the brain, heart, skin, and other organs. Germline defects in Tsc-2 predispose to both benign (hamartoma) and malignant (RCC) renal tumors (19) . Tumors that develop in Eker rats exhibit somatic alterations of the wild-type allele as predicted by Knudson's tumor suppressor gene paradigm (38, 91) and reintroduction of the wild-type Tsc-2 gene into tumor cells suppresses cell growth in vitro and in vivo (33) . Cell lines have been established from spontaneous Eker rat RCCs and the availability of these lines and ready access to primary tumor material has made it possible to establish the similarity of this rodent model to the human disease. Table I1 below outlines the major comparisons that have been made between the rodent and human disease using the Eker rat model.
Iiivolvenient of VHL and Tsc-2 in Rat and Hiwiaii RCC
Interestingly, the involvement of the VHL and Tsc-2 tumor suppressor genes in tumorigenesis appears to be species specific. Experiments in which mutations in the rat VHL gene were examined using single-strand conformation polymorphisddirect sequencing indicated that the VHL gene was not a target for alterations in Eker rat tumors (78) . This finding has subsequently been confirmed in the Eker model as well as for carcinogen-induced tumors in other rat strains (35, 66) . The involve- ment of the Tsc-2 tumor suppressor gene in rat RCC and the VHL tumor suppressor gene in human RCC presents an interesting molecular dichotomy in the etiology of tumor development in these 2 species. Resolution of this dichotomy is important for several reasons. If rodent renal tumorigenesis is modulated by genetic targets other than those involved in human renal carcinogenesis, there are important implications for chemical risk assessments that utilize animal models to assess carcinogenic potential, especially as kidney tumors are the most frequent lesion observed in male rats in the NTP bioassay (1, 71) . More importantly, these data suggest that context constraints exist for the action of the VHL tumor suppressor gene that can limit its ability to participate in renal carcinogenesis. An understanding of why the VHL tumor suppressor gene does not cause renal tumors in rats may reveal insights into its mechanism of action and/or modifiers of its activity that could be useful in developing novel therapeutic targets for human RCC in which the VHL gene is involved. Although the VHL tumor suppressor gene is expressed and presumably serving an important normal function in the rat, as mentioned above, it does not appear to be a target for renal carcinogenesis (35, 66, 78) . Conversely, there are no data indicating that the human Tsc-2 tumor suppressor gene plays a significant role in the development of sporadic human RCC. In addition to this apparent species-specific constraint, there also appears to be cell type-specific limitations on the action of the VHL and Tsc-2 tumor suppressor genes. Germline alterations in the VHL and Tsc-2 tumor suppressor genes in humans and rats, respectively, only predispose to a very limited number of tumor types, even though these genes are ubiquitously expressed. More specifically, in the Eker rat we have shown that although they both carry Tsc-2 mutations, kidney epithelial cells but not renal mesenchymal cells are predisposed to tumor development even when challenged by chemical carcinogens that transform both cell types (8 1). The presence of these context constraints appears to be a general phenomenon that determines the activity of many other tumor suppressor genes as well, which, although they are ubiquitously expressed and have important normal cell functions, such as regulation of cell cycle progression by RB, only participate in the development of, or predispose to, a limited number of tumor types. 
STAGING MOLECULAR EVENTS IN RCC
In human RCC, patients generally present with very late-stage disease, making it very difficult to analyze early lesions to determine the progression sequence of events involved in RCC. This type of information would be very useful to identify candidate targets for therapeutic andor preventative strategies where intervention would be most effective at specific stages of the disease. Our ability to access tumors at all stages of development in the Eker rat model, from early lesions to the establishment of cell lines in vitru, has made it possible for us to stage alterations involved in RCC. Figure 3 summarizes data on alterations associated with specific stages of RCC in the rat.
TGF-n Overexpression in RCC
Studies in human tumors have found that epithelial growth factor receptor (EGF-R) and transforming growth factor (TGF-a) are overexpressed in the vast majority of RCCs (6, 18, 49, 57, 78) . TGF-a is also overexpressed in rat RCC and participates in an autocrine loop in these tumor cells (79) , suggesting a similar role for these genes in disease pathogenesis in both species. Using an immunohistochemical approach, it was demonstrated that altered expression of TGF-a occurs very early in the development of RCC (14). Adenomas and even preneoplastic dysplastic tubules overexpressed TGF-a, in contrast to proximal tubule epithelial cells of the renal nephron (the progenitors of RCC) that do not express significant amounts of TGF-a. Expression of TGF-a therefore appears to be the earliest biomarker identified to date for RCC, being overexpressed in the earliest preneoplastic lesions that are histologically identifiable. Interestingly, TGF-a expression correlated with preneoplasia and not just cell proliferation per se, as areas of renal nephropathy associated with aging, in which proliferation is high due to compensatory regeneration of tubular epithelial cells but that are not associated with neoplastic changes, did not express TGF-a. In addition, as TGF-a overexpression occurred very early, in some cases in lesions containing only a few cells, it is unlikely that additional genetic alterations other than loss of the normal allele of the Tsc-2 gene (which occurs early in tumor development (43) ) are required to deregulate TGF-a expression.
p53 and ras Miitations in RCC
Similar to the human disease in which p53 mutations are infrequent andor late events (27, 30, 32, 5 1. 60, 74, 75) , mutations in the p53 tumor suppressor gene are not detected in Eker rat tumors or cell lines (28) . Similar data are available for alterations in ras family oncogenes (59), as neither rat nor human RCC exhibit a significant frequency of mutations in these oncogenes.
p15 mid p16 Tiunor Suppressor Genes
It has been reported previously that monosomy 5 occurred with a high frequency in rat RCC cell lines (15), suggesting that a tumor suppressor gene resided on this chromosome. Subsequent studies identified p15/p16 as the target for chromosome 5 alterations in RCC cell lines (36) and established that these alterations occurred as "late" events in cell lines and only infrequently in primary tumors. Similar studies on these tumor suppressor genes in humans reported that alterations in these genes were observed in RCC cell lines but not primary tumors (2), indicating a similar role for these genes in disease pathogenesis of both rat and human RCC . Taken together with data on TGF-a, ras, and p53, it appears that downstream from the initiating events at the VHL or Tsc-2 loci, significant similarity exists at the molecular level between human and rat RCC (13, 80) .
Siomriary
RCC is a histologically and cytologically heterogeneous disease that carries with it a poor prognosis and significant diagnostic challenges. Several of the genes involved in RCC have recently been identified, making it possible now to perform functional molecular genetic studies for RCC to enhance our ability to diagnose and treat this disease. Data from human and rodent studies indicate that the VHL, Tsc-2 tumor suppressor genes, and c-met protooncogene are targets for genetic alterations in the development of RCC and that aberrant expression of other genes such as Pax-2, TGF-a, and VEGF participate in this process as well.
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